The trial of the company’s metastatic pancreatic cancer treatment, elraglusib, similarly saw the one-year survival rate reach ...

Statistical Significance Met on Primary Endpoints of 1 Year Survival Rate and Median Overall SurvivalDoubling of 1 Year ...

Shares of Actuate Therapeutics on Tuesday climbed after the company said that it received positive data from its phase 2 trial of elraglusib in combination with gemcitabine/nab-paclitaxel to treat ...

The researchers found that administering 75 grams of vitamin C three times a week doubled overall survival rates of patients ...

Marker Therapeutics (NASDAQ:MRKR) shares popped 11% Tuesday morning after the immuno-oncology company won a $9.5M grant from ...

Pancreatic cancer can be a silent killer -- the organ is located deep inside the body, making cancer harder to detect before ...

The FDA advised that the on-going VIRAGE Phase 2b study should not be expanded into a Phase 3 study; rather, the optimal path forward for the VCN-01 PDAC program is to conduct a stand-alone Phase 3 ...

Well, the company is already in the process of exploring the use of TTFields + TECENTRIQ + Gemcitabine + nab-paclitaxel for the treatment of 1st-line metastatic pancreatic cancer patients.

Pancreatic cancer is a disease in which malignant cells originate in the pancreatic tissue. Cancer of the exocrine component of the pancreas (adenocarcinomas) represents the majority of pancreatic ...

Dec. 12, 2024 — Researchers have successfully developed a deep learning model that classifies pancreatic ductal adenocarcinoma (PDAC), the most common form of pancreatic cancer, into molecular ...

Pulmonary metastases occur also very often in sarcoma, a relatively rare type of cancer. As many as 20% of soft tissue sarcomas and up to 40% of bone sarcomas develop lung metastases. Occasionally, ...

The increase in incidence of pancreatic cancer among young Americans is largely due to improved detection of early-stage endocrine cancer, not an increase in pancreatic adenocarcinoma. Given the ...